BioSpace News Archive

Milestone Pharmaceuticals Inc. today announced significant progress in clinical and regulatory activities for etripamil, the Company’s investigational calcium channel blocker that is administered by patients outside of the healthcare setting to treat paroxysmal supraventricular tachycardia (PSVT).

HanAll Biopharma Co., Ltd. (KRX: 009420. KS) announced that its licensed partner Harbour BioMed in Greater China reported positive top-line results from its pivotal Phase 3 clinical trial of batoclimab in generalized myasthenia gravis (gMG) patients.

Smith+Nephew announces a systemic literature review and meta-analysis of its VISIONAIRE Patient-Specific Instrumentation showing that its use leads to improvements in alignment accuracy, efficiency in surgical procedures, and reduction in length of hospital stay in comparison with conventional instrumentation.1

Congruence Therapeutics, a biotechnology company working at the interface of computational and experimental drug discovery to design novel small molecules for diseases of protein misfolding, announced today the close of an extension to its Series A financing, bringing the total amount raised to over US$65 million.

Corbus Pharmaceuticals Holdings, Inc., a precision oncology company, announced the appointment of Yong Ben, M.D., MBA, to the Company’s Board of Directors.

Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) (“Acurx” or the “Company”), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that the Company will discuss its fourth quarter 2022 and fiscal year end 2022 financial results on Thursday, March 16, 2022, at 8:00 am ET before the U.S. financial markets open.

Cantex Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has issued a “Study May Proceed” letter for the Miami Cancer Institute’s investigator initiated clinical trial to assess the safety and effectiveness of azeliragon combined with stereotactic radiosurgery in patients with brain metastases.

Rallybio Corporation (Nasdaq: RLYB) today reported financial results for the fourth quarter and full year ended December 31, 2022 and provided an update on recent program and corporate developments.

Astria Therapeutics, Inc. today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will present a corporate overview and provide information on lead program STAR-0215 at the upcoming virtual Oppenheimer 33rd Annual Healthcare Conference on Monday, March 13th at 1:20pm ET.

Edgewise Therapeutics, Inc. announced today the appointment of Jonathan C. Fox, M.D., Ph.D., FACC, to its Board of Directors.